Shelf registration statement covering 1.5 mil. common shares filed with Securities & Exchange Commission. Proceeds will primarily be used to pay for recent Invenex and Bristoject acquisitions. In addition, Fujisawa will purchase 500,000 shares in a private transaction that will maintain its stake in LyphoMed at about 26.5%.
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."